Orin Green Financial LLC Purchases 11,200 Shares of Protalix BioTherapeutics, Inc. $PLX

Orin Green Financial LLC lifted its position in Protalix BioTherapeutics, Inc. (NYSE:PLX) by 22.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 61,200 shares of the company’s stock after purchasing an additional 11,200 shares during the quarter. Orin Green Financial LLC owned 0.08% of Protalix BioTherapeutics worth $91,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. NewEdge Advisors LLC bought a new stake in shares of Protalix BioTherapeutics in the 1st quarter worth about $39,000. Cubist Systematic Strategies LLC grew its holdings in shares of Protalix BioTherapeutics by 82.1% in the 1st quarter. Cubist Systematic Strategies LLC now owns 53,380 shares of the company’s stock worth $137,000 after purchasing an additional 24,073 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Protalix BioTherapeutics in the 1st quarter worth about $107,000. Stratos Wealth Partners LTD. lifted its position in Protalix BioTherapeutics by 28.3% during the 1st quarter. Stratos Wealth Partners LTD. now owns 346,400 shares of the company’s stock worth $887,000 after buying an additional 76,400 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new stake in Protalix BioTherapeutics during the 1st quarter worth about $459,000. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Stock Down 22.5%

Shares of NYSE:PLX opened at $1.86 on Monday. Protalix BioTherapeutics, Inc. has a 12 month low of $1.01 and a 12 month high of $3.10. The company’s 50-day moving average price is $1.91 and its two-hundred day moving average price is $1.87. The firm has a market cap of $148.30 million, a P/E ratio of -14.31 and a beta of -0.13.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.